Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics. [PDF]
J Ovarian Res, 2021 Franz A +5 more
europepmc +1 more source
Pyruvate Kinase M2 Mediates Apigenin‐Induced Energy Crisis and Apoptosis in Colon Cancer Cells
Food Frontiers, Volume 7, Issue 4, July 2026.Apigenin, a dietary flavonoid with low toxicity, induces profound bioenergetic collapse in colon cancer cells by downregulating PKM2. This metabolic crisis, characterized by suppressed glycolysis and mitochondrial dysfunction, ultimately triggers robust apoptosis.
Ke Zhang +3 more
wiley +1 more source
Poly(ADP-ribose) polymerase (PARP) inhibitors have proven their efficacy for treating tumors defective in homologous recombination via synthetic lethality.
Duxin, Julien P. +20 more
core +1 more source
Targeting PCNA/PARP1 axis inhibits the malignant progression of hepatocellular carcinoma
Frontiers in PharmacologyIntroductionProliferating cell nuclear antigen (PCNA) is associated with the proliferation and recurrence of various cancers, and its high expression is associated with poor prognosis in hepatocellular carcinoma (HCC) patients. However, the mechanistic role of PCNA in HCC progression remains poorly understood.
Jipin Li +8 more
openaire +3 more sources
Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy
MedComm, Volume 7, Issue 7, July 2026.Tumor progression is driven by heterogeneity occurring across multiple biological scales. At the molecular level, tumor cells exhibit alterations across distinct omics layers, including genomic mutations, epigenomic reprogramming, transcriptional changes, and proteomic remodeling, collectively shaping tumor cell phenotypes and functional states.
Hanwen Hu +5 more
wiley +1 more source
, 2019 Higher doses of olaparib are sufficient to inhibit PAR formation in BRCA1-mutant SUM-149 cells. At higher concentrations of olaparib (1μM), combination treatment of PARP1 inhibition and radiation decreases PAR in a comparable manner to lower doses of ...
Lori J. Pierce (8435880) +15 more
core +1 more source
Poly (ADP-ribose) polymerase 1 (PARP1) inhibition promotes pulmonary metastasis of osteosarcoma by boosting ezrin phosphorylation. [PDF]
Int J Biol Sci, 2022 Li F +7 more
europepmc +1 more source
RNA Modifications in Tumor Microenvironment: A New Dimension for Cancer Treatment
MedComm, Volume 7, Issue 7, July 2026.Tumor initiation and progression depend on a supportive and highly heterogeneous tumor microenvironment (TME). RNA modifications regulate signaling pathways and cytokine networks that shape TME dynamics, facilitating interactions between cancer cells and noncancerous stromal cells, and ultimately promoting immune evasion and tumor progression ...
Qiwen Li +3 more
wiley +1 more source
PARP1 is required for adhesion molecule expression in atherogenesis
, 2017 Aims Atherosclerosis is the leading cause of death in Western societies and a chronic inflammatory disease. However, the key mediators linking recruitment of inflammatory cells to atherogenesis remain poorly defined. Poly(ADP-ribose) polymerase 1 (PARP1)
Stähli, Barbara E. +13 more
core
Abstract A26: Impact of PARP1 on AR signaling and therapeutic response in prostate cancer
, 2010 Poly (ADP-ribose) polymerase 1 (PARP1) modifies various nuclear proteins by poly (ADP-ribose)-ylation, and has a known role in a multitude of chromatin-associated functions, including: transcriptional coregulation, modification of chromatin structure ...
Karen A. Knudsen +2 more
core +1 more source